沟通传递价值 信心共筑未来——2025年上海辖区上市公司集体接待日暨中报业绩说明会9月19日在全景 网举行。卫宁健康（300253）董事长周炜表示，目前公司有不少项目在推进中。WiNGPT Copilot智能 助手已在近150家医院部署，覆盖智能问诊、病历质控等100+场景，并与浙江省中医院、上海市肺科医 院联合开发专科AI模型等。 卫宁健康创立于2004年，自成立以来一直集研发、销售和技术服务为一体，为客户提供"一体化"的解决 方案。公司致力于提供医疗健康卫生信息化解决方案，不断提升人们的就医体验和健康水平。通过持续 的技术创新，自主研发适应不同应用场景的产品与解决方案，业务覆盖智慧医院、区域卫生、基层卫 生、公共卫生、医疗保险、健康服务等领域，是中国医疗健康信息行业具有竞争力的整体产品、解决方 案与服务供应商。（全景网） ...

Core Insights - The event highlighted the ongoing projects of Weining Health, including the deployment of the WiNGPT Copilot intelligent assistant in nearly 150 hospitals, covering over 100 scenarios such as smart consultations and medical record quality control [1] Company Overview - Weining Health, founded in 2004, integrates research, sales, and technical services to provide comprehensive solutions in the healthcare information sector [1] - The company focuses on enhancing patient experience and health levels through continuous technological innovation and self-developed products tailored for various application scenarios [1] Business Scope - Weining Health's business encompasses smart hospitals, regional health, grassroots health, public health, medical insurance, and health services, positioning it as a competitive provider of integrated products, solutions, and services in China's healthcare information industry [1]

Core Viewpoint - The recent financial report of Chuangye Huikang (300451) indicates a significant decline in revenue and net profit for Q1 2025 compared to the same period in 2024, raising concerns about the company's financial health and operational efficiency [1][3]. Financial Performance Summary - Total revenue for Q1 2025 was 290 million yuan, a decrease of 22.67% year-on-year from 375 million yuan in Q1 2024 [1]. - The net profit attributable to shareholders for Q1 2025 was -15.64 million yuan, representing a decline of 226.6% compared to a profit of 12.36 million yuan in Q1 2024 [1]. - The gross profit margin improved to 55.12%, an increase of 6.8% year-on-year, while the net profit margin fell to -5.06%, a decrease of 233.34% [1]. - Total receivables accounted for 114.01% of the latest annual revenue, indicating a high level of outstanding payments [1]. Cost and Expense Analysis - Total expenses (sales, management, and financial) amounted to 78.54 million yuan, which is 27.05% of revenue, reflecting a year-on-year increase of 21.54% [1]. - The company reported a significant increase in interest-bearing liabilities, rising by 400.02% to 54.88 million yuan [1]. Market and Operational Insights - The decline in revenue is attributed to the company's client base, primarily public medical institutions, which face strict budget controls and lengthy procurement processes [3]. - The uneven distribution of payment schedules and project acceptance has been influenced by external market conditions and the transition between old and new products [3]. Business Model and Financing - The company has relied heavily on equity financing, with a total financing amount of 2.814 billion yuan and cumulative dividends of 230 million yuan since its listing, resulting in a dividend-to-financing ratio of 0.08 [4].